Lukas Biomedical

Lukas Biomedical Current Assets

The Current Assets of Lukas Biomedical (6814.TWO) as of Oct 28, 2026 is 36.92 M TWD. In the previous year, Current Assets was 124.50 M TWD — a change of -70.35% (lower).

Current Assets

36.92 MTWD

YoY

-70.35%

Last updated:

Current Assets of Lukas Biomedical is 2025 36.92 M TWD. Current Assets of Lukas Biomedical was 2024 124.50 M TWD. It decreases by -70.35% lower compared to the previous year.

The Lukas Biomedical Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
109.05 M TWD
Jan 1, 2019
75.61 M TWD
Jan 1, 2020
80.03 M TWD
Jan 1, 2021
120.53 M TWD
Jan 1, 2022
105.53 M TWD
Jan 1, 2023
87.37 M TWD
Jan 1, 2024
124.50 M TWD
Jan 1, 2025
36.92 M TWD
The Lukas Biomedical Current Assets history
YEARCurrent AssetsYoY
36.92 MTWD-70.35%
124.50 MTWD+42.49%
87.37 MTWD-17.21%
105.53 MTWD-12.45%
120.53 MTWD+50.60%
80.03 MTWD+5.86%
75.61 MTWD-30.67%
109.05 MTWD-2.77%
112.16 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lukas Biomedical Stock analysis

What does Lukas Biomedical do? Lukas Biomedical, Inc. generates revenue through the lease and sale of medical equipment, as well as the research, design, development, and manufacture of immune cell products. The company offers beauty cosmetics, skin care products, and daily necessities such as dental floss, chewing gum, chewing spray, and dry hair products. Its makeup series includes eye shadow gel, eye color palette, lip gloss, lipstick, and lip wax. The firm provides services like brand authorization, management consulting, property leasing, and medical equipment leasing under an experience charging model for care institutions and medical management. The company’s products target consumers in the beauty and healthcare sectors, with medical equipment leased to care institutions and medical management entities. Immune cell products are developed for medical applications, while beauty and daily necessity products cater to personal care markets. The firm’s service model combines brand authorization with property and equipment leasing to support operational experience in healthcare facilities. Lukas Biomedical’s revenue streams include direct sales of medical equipment, lease agreements for medical devices, and the sale of immune cell products, beauty cosmetics, and daily necessities. Care institutions and medical management companies are key clients for leasing services, while beauty product lines serve individual consumers and retail channels. The experience charging model integrates brand authorization and management consulting to enhance service offerings for healthcare providers. Lukas Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lukas Biomedical stock

Current Assets of Lukas Biomedical is 36.92 M TWD in 2025.

Current Assets of Lukas Biomedical changed from 124.50 M TWD to 36.92 M TWD, representing a -70.35% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Lukas Biomedical since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Lukas Biomedical historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Lukas Biomedical

All Key Metrics — Lukas Biomedical